These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24813570)

  • 21. Prevalence and correlates of psychotropic medication use in adolescents with an autism spectrum disorder with and without caregiver-reported attention-deficit/hyperactivity disorder.
    Frazier TW; Shattuck PT; Narendorf SC; Cooper BP; Wagner M; Spitznagel EL
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):571-9. PubMed ID: 22166171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of inter-practice variation in ADHD diagnosis and stimulant prescribing: cross-sectional database study of a national surveillance network.
    Hoang U; James AC; Liyanage H; Jones S; Joy M; Blair M; Rigby M; Lusignan S
    BMJ Evid Based Med; 2019 Aug; 24(4):155-161. PubMed ID: 30765384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.
    Zito JM; Safer DJ; dosReis S; Magder LS; Gardner JF; Zarin DA
    Arch Pediatr Adolesc Med; 1999 Dec; 153(12):1257-63. PubMed ID: 10591302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.
    Brinker A; Mosholder A; Schech SD; Burgess M; Avigan M
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):328-33. PubMed ID: 17630866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
    Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD.
    Brikell I; Wimberley T; Albiñana C; Pedersen EM; Vilhjálmsson BJ; Agerbo E; Demontis D; Børglum AD; Schork AJ; LaBianca S; Werge T; Mors O; Hougaard DM; Thapar A; Mortensen PB; Dalsgaard S
    Am J Psychiatry; 2021 Sep; 178(9):854-864. PubMed ID: 34154395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects associated with on- and off-label stimulant treatment of core autism and ADHD symptoms exhibited by children with autism spectrum disorder.
    Barnard-Brak L; Davis TN; Schmidt M; Richman DM
    Dev Neurorehabil; 2016; 19(1):46-53. PubMed ID: 24739141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors Associated with Attention Deficit Hyperactivity Disorder Medication Use in Community Care Settings.
    Kamimura-Nishimura KI; Epstein JN; Froehlich TE; Peugh J; Brinkman WB; Baum R; Gardner W; Langberg JM; Lichtenstein P; Chen D; Kelleher KJ
    J Pediatr; 2019 Oct; 213():155-162.e1. PubMed ID: 31300310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.
    Preen DB; Calver J; Sanfilippo FM; Bulsara M; Holman CD
    Aust N Z J Public Health; 2007 Apr; 31(2):120-6. PubMed ID: 17461001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design.
    Raman SR; Marshall SW; Haynes K; Gaynes BN; Naftel AJ; Stürmer T
    Inj Prev; 2013 Jun; 19(3):164-70. PubMed ID: 23143347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study.
    Barbaresi WJ; Katusic SK; Colligan RC; Weaver AL; Leibson CL; Jacobsen SJ
    J Dev Behav Pediatr; 2014 Sep; 35(7):448-57. PubMed ID: 25180895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
    Molina BS; Hinshaw SP; Eugene Arnold L; Swanson JM; Pelham WE; Hechtman L; Hoza B; Epstein JN; Wigal T; Abikoff HB; Greenhill LL; Jensen PS; Wells KC; Vitiello B; Gibbons RD; Howard A; Houck PR; Hur K; Lu B; Marcus S;
    J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):250-63. PubMed ID: 23452682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preschool ADHD Diagnosis and Stimulant Use Before and After the 2011 AAP Practice Guideline.
    Fiks AG; Ross ME; Mayne SL; Song L; Liu W; Steffes J; McCarn B; Grundmeier RW; Localio AR; Wasserman R
    Pediatrics; 2016 Dec; 138(6):. PubMed ID: 27940706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Physical Injuries: A Systematic Review and Meta-Analysis of Observational Studies.
    Man KKC; Ip P; Chan EW; Law SL; Leung MTY; Ma EXY; Quek WT; Wong ICK
    CNS Drugs; 2017 Dec; 31(12):1043-1055. PubMed ID: 29255995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of medication by young people with attention-deficit/hyperactivity disorder.
    Sawyer MG; Rey JM; Graetz BW; Clark JJ; Baghurst PA
    Med J Aust; 2002 Jul; 177(1):21-5. PubMed ID: 12088474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attention-Deficit/Hyperactivity Disorder Medication Treatment Impact on Response to Growth Hormone Therapy: Results from the ANSWER Program, a Non-Interventional Study.
    Rose SR; Reeves G; Gut R; Germak J
    J Pediatr; 2015 Dec; 167(6):1389-96. PubMed ID: 26394822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.